2024年美国临床肿瘤学会（ASCO）年会将于2024年5月31日至6月4日在美国伊利诺伊州芝加哥举行。目前，ASCO官网已公布了本次会议的日程和摘要题目。【肿瘤资讯】整理了口头报告专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）和摘要速递专场（Rapid Oral Abstract Session）的乳腺肿瘤研究，与读者分享。
摘要速递专场——乳腺癌-局部/区域/辅助
Breast Cancer—Local/Regional/Adjuvant
专场时间：6月1日 03:45-05:15（以下均为北京时间）
专场主席：Norah Lynn Henry, MD, PhD, FASCO, FACP University of Michigan Rogel Cancer Center；Puneet Singh, MD, FACS The University of Texas MD Anderson Cancer Center
摘要号：LBA509
I-SPY2.2试验的结果：datopotamab deruxtecan(Dato)新辅助治疗后的病理学完全缓解 (pCR) 率
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial
讲者: Jane Lowe Meisel, MD | Winship Canter Institute of Emory University
摘要号：511
MammaPrint 指数与接受含蒽环类或不含蒽环类药物化疗的HR+/HER2-早期乳腺癌患者的3年结局的相关性
Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline
讲者: Joyce O'Shaughnessy, MD | Baylor University Medical Center, Texas Oncology, The US Oncology Network
摘要号： 512
NATALEE试验：淋巴结阴性HR+/HER2-早期乳腺癌患者的基线特征和疗效终点
Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial
讲者: Denise A. Yardley, MD | Sarah Cannon Research Institute
摘要号：513
豁免辅助内分泌治疗对ER低表达(1-10%) 早期乳腺癌的影响
The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer
讲者: Grace Mei Yee Choong, MD | Mayo Clinic
摘要号：514
基于初次全身治疗后cN1乳腺癌患者反应导向的腋窝治疗的肿瘤学结局
Oncologic outcome of response-guided axillary treatment in patients with cN1 breast cancer after primary systemic therapy.
讲者: Annemiek van Hemert, MD | Antoni van Leeuwenhoek / Netherlands Cancer Institute
摘要号：515
RxPONDER试验：按人种和种族列出的复发评分基因轴评分和结局
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial
讲者: Yara Abdou, MD | The University of North Carolina at Chapel Hill
摘要号：516
GEICAM/2003-11_CIBOMA/2004-01试验：OXC1表达定义的非基底亚型是卡培他滨治疗TNBC疗效的独立预测因子
Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial
讲者: Federico Gustavo Rojo Todo, MD, PhD | Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group
摘要号：517
在不同的乳腺癌队列中，预测性生物标志物MHC-I和MHC-II与临床和分子特征的相关性
Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort
讲者: Sonya A. Reid, MD, MPH | Vanderbilt University Medical Center
口头报告专场——转移性乳腺癌
Breast Cancer—Metastatic
专场时间：6月2日 04:00-07:00
专场主席：Anne F. Schott, MD University of Michigan Rogel Cancer Center；Antonio Di Meglio, MD, PhD Cancer Survivorship Program, INSERM 981, Gustave Roussy
摘要号：LBA1001
Ⅲ期临床试验postMONARCH的主要结局：阿贝西利+氟维司群 vs 氟维司群单药治疗既往CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial
讲者: Kevin Kalinsky, MD, MS | Winship Cancer Institute of Emory University
摘要号：LBA1002
哌柏西利+依西美坦联合GnRH 激动剂 vs 卡培他滨治疗绝经前HR+/HER2-转移性乳腺癌：Young-PEARL随机 II 期研究更新的生存结局
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL
讲者: Yeon Hee Park, MD, PhD | Samsung Medical Center, Sungkyunkwan University
摘要号：1003
III期随机试验INAVO120的额外分析：一线inavolisib/安慰剂+哌柏西利+氟维司群 (Inavo/Pbo+Palbo+Fulv)用于辅助内分泌治疗完成期间/12个月内复发的 PIK3CA突变、HR+/HER2-局晚期/转移性乳腺癌
First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2 negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses
讲者: Dejan Juric, MD | Medicine-Hematology and Medical Oncology, Massachusetts General Hospital Cancer Center
摘要号：LBA1004
随机II期试验SACI-IO HR+：戈沙妥珠单抗±帕博利珠单抗治疗转移性HR+/HER2-乳腺癌
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer
讲者: Ana Christina Garrido-Castro, MD | Dana-Farber Cancer Institute
摘要号：1005
EV-202研究中，TNBC和HR+/HER2-乳腺癌队列中Enfortumab vedotin (EV)的应用
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202
讲者: Antonio Giordano, MD, PhD | Dana-Farber Cancer Institute
摘要号：1006
TROPION-Breast01研究中患者报告的结局：Dato-DXd vs化疗用于既往经治的不可切除或转移性HR+/HER2-乳腺癌
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
讲者: Sonia Pernas, MD, PhD | Institut Català d'Oncologia, IDIBELL, L’Hospitalet
摘要号：1007
曲妥珠单抗+帕妥珠单抗联合艾立布林或紫杉醇作为HER2+、局部晚期或转移性乳腺癌的一线化疗：日本多中心、随机、非劣效性Ⅲ期试验（JBCRG-M06/EMERALD）的结果
Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD)
讲者: Toshinari Yamashita, MD, PhD | Kanagawa Cancer Center
摘要号：1008
随机 II 期研究PATRICIA 队列 C (SOLTI-1303) 的主要结果：评价哌柏西利联合曲妥珠单抗和内分泌治疗用于既往经治HER2+和PAM50 luminal型乳腺癌
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.
讲者: Eva Ciruelos, MD, PhD | Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre
摘要号：1009
DESTINY-Breast07：在既往未经治疗的HER2+ mBC患者中进行的 T-DXd 单药治疗和T-DXd+帕妥珠单抗的剂量扩展中期分析
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
讲者: Fabrice Andre, MD, PhD | Gustave Roussy, Université Paris-Saclay
临床科学研讨会——新一代ADC药物
Next-Generation Antibody–Drug Conjugates: The Revolution Continues
专场时间：6月2日 22:45-0:15
专场主席：Erika P. Hamilton, MD Sarah Cannon Research Institute
摘要号：104
III期OptiTROP-Breast01研究：Sacituzumab tirumotecan(SKB264/MK-2870) 用于既往接受过治疗的局部复发或转移性TNBC
Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study
讲者：樊英教授 | 中国医学科学院肿瘤医院
临床科学研讨会——ctDNA在乳腺癌中的应用
The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer
专场时间：6月3日 05:30-7:00
专场主席：Manali A. Bhave, MD Emory University School of Medicine；Maryam B. Lustberg, MD Yale School of Medicine
摘要号：1010
超敏ctDNA突变追踪，用于识别早期乳腺癌患者的分子残留疾病并预测复发
Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer
讲者: Isaac Garcia-Murillas, PhD | Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research
摘要号：1011
GEICAM/2014-03_RegistEM登记研究中，管腔型乳腺癌对辅助 ET 治疗的内分泌耐药性/敏感性的综合临床特征和ctDNA突变谱分析
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry
讲者: Angel Guerrero, MD | Instituto Valenciano de Oncología (IVO); GEICAM Spanish Breast Cancer Group
摘要号：1012
MONALEESA-3(ML-3) 研究：治疗中的ctDNA动态变化 (∆ctDNA)与HR+/HER2-晚期乳腺癌（ABC）患者的无进展生存期 (PFS) 和总生存期 (OS) 的相关性
On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3)
讲者: Stephen K. L. Chia, MD, FRCPC | BC Cancer
摘要速递专场——转移性乳腺癌
Breast Cancer—Metastatic
专场时间：6月4日 00:30-2:00
专场主席：Erica Michelle Stringer-Reasor, MD O'Neal Comprehensive Cancer Center at UAB；Amy Sanders Clark, MD, MSCE Perelman School of Medicine at the University of Pennsylvania
摘要号：1014
在HR+/HER2-ABC患者中比较一线哌柏西利、瑞波西利或阿贝西利的抗肿瘤疗效：意大利多中心、真实世界、PALMARES-2研究的结果
Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2
讲者: Claudio Vernieri, MD, PhD, PhD (c) | Fondazione IRCCS INT
摘要号：1015
H3B-6545在局晚期/转移性ER+/HER2-乳腺癌女性中的应用
H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC)
讲者: Erika P. Hamilton, MD | Sarah Cannon Research Institute
摘要号：1016
SONIA试验：接受内分泌治疗±CDK4/6抑制剂治疗的HR+晚期乳腺癌患者的认知功能
Cognitive function in patients with HR+ advanced breast cancer treated with endocrine therapy with or without CDK4/6 inhibitors in the SONIA trial
讲者: Maryse Luijendijk, MSc | Psychosocial Research and Epidemiology, Netherlands Cancer Institute
摘要号：1017
ER+/HER2-转移性乳腺癌中的种族基因组特征及靶向治疗应用差异
Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer.
讲者: Emily L Podany, MD | Washington University in St. Louis
摘要号：1018
乳腺癌脑转移的基因组和肿瘤微环境动态
Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.
讲者: DHARMINI MANOGNA, MD | Tulane Medical University
摘要号：1019
分子影像在新诊断的转移性乳腺癌中的临床应用
Clinical utility of molecular imaging in newly diagnosed metastatic breast cancer.
讲者: Carolina Pia Schroder, MD, PhD | Department of Medical Oncology, Netherlands Cancer Institute
摘要号：1020
ACE-Breast-02：ARX788（一种新型抗HER2 ADC）与拉帕替尼联合卡培他滨治疗HER2+晚期乳腺癌的关键2/3期试验
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC)
讲者: 胡夕春教授 | 复旦大学附属肿瘤医院
摘要号：1021
Ⅱ期研究TBCRC 048 (奥拉帕利扩展)扩展队列：奥拉帕利单药治疗携带gPALB2突变或体细胞BRCA1/2突变的转移性乳腺癌
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
讲者: Nadine M. Tung, MD, FASCO | Beth Israel Deaconess Medical Center
摘要号：1022
BRIA-IMT（一种同种异体全细胞免疫治疗）治疗晚期/转移性乳腺癌的结局
Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.
讲者: Carmen Julia Calfa, MD | Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
口头报告专场——乳腺癌-局部/区域/辅助
Breast Cancer—Local/Regional/Adjuvant
专场时间：6月4日 04:00-07:00
专场主席：Cesar Augusto Santa-Maria, MD, MS Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins；Laura Stewart Dominici, MD Brigham and Women's Hospital
摘要号： LBA500
随机III期A-BRAVE试验：阿维鲁单抗治疗新辅助化疗后有残留病灶或初次手术和辅助化疗后高危的早期TNBC
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
讲者: Pier Franco Conte, MD | Department of Surgery Oncology and Gastroenterology, University of Padua
摘要号：LBA501
I-SPY2.2试验：datopotamab deruxtecan（Dato）联合度伐利尤单抗在新辅助治疗中的pCR率
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
讲者: Rebecca Arielle Shatsky, MD
摘要号：LBA502
一项在早期TNBC患者中比较蒽环类药物序贯紫杉烷与蒽环类药物序贯紫杉烷+卡铂作为（新）辅助治疗的随机、多中心、开放性、III期试验：韩国癌症研究组 BR 15-1 PEARLY 试验
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial
讲者: Joohyuk Sohn, MD, PhD | Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine
摘要号：503
ECOG-ACRIN EAZ171前瞻性验证性研究：分析种系突变和紫杉烷类型与黑人女性早期乳腺癌患者紫杉烷诱导的周围神经病变（TIPN）的关联
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer
讲者: Tarah Jean Ballinger, MD | Indiana University Simon Comprehensive Cancer Center
摘要号： 504
激素受体状态和肿瘤亚型对年轻BRCA携带者乳腺癌的临床行为和结果的影响
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.
讲者: Luca Arecco, MD | Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy and Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB)
摘要号：505
血清抗苗勒氏管激素 (AMH) 水平与鉴别绝经前HR+/HER2-、淋巴结阳性乳腺癌患者的相关性，这些患者最有可能从 SWOG S1007(RxPONDER) 的辅助化疗中获益
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
讲者: Kevin Kalinsky, MD, MS | Winship Cancer Institute, Emory University
摘要号：506
阐明HR+/HER2- MammaPrint High 2早期乳腺癌的免疫活性状态
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
讲者: Erin Frances Cobain, MD | University of Michigan
摘要号：LBA507
monarchE试验（阿贝西利+内分泌治疗用于HR+、HER2-、淋巴结阳性、高风险早期乳腺癌）中ctDNA检测的预后效果
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
讲者: Sherene Loi, MD, PhD | Peter MacCallum Cancer Centre
摘要号：508
HR+/HER2-、淋巴结阳性乳腺癌中RSClin N+ 工具的开发和验证
Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
讲者：Lajos Pusztai, MD, PhD, FASCO, D.Phil | Yale University Cancer Center
排版编辑：肿瘤资讯-张薪媛
苏公网安备 32059002004080号
